Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the known differences in genes influence drug
metabolizing enzymes and receptors that are involved in risperidone drug action. The study
will determine if differences in these genes will change the concentration of risperidone in
the blood over time in children in relation to side effects and clinical response to
risperidone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)